Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 and M9241 with SBRT in Advanced Pancreas Cancer
NCT04327986Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2021
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa, NHS-IL-12 in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Started Jun 2021; status: terminated.
02
Drugs
bintrafusp alfaNHS-IL-12
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04327986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327986.